Eli Lilly and Company has entered into an agreement with Innovent Biologics for the commercialisation of Verzenios in mainland China.

The US FDA has declined to approve Unicycive Therapeutics’ resubmitted NDA for OLC to treat hyperphosphatemia in CKD patients on dialysis.

Less than a year after emerging from stealth, Danish-based QuantumCell has signed a multi-billion-dollar deal to equip its pipeline with Alzheimer’s drug technology. The biotech has entered into a ...

Eli Lilly’s retatrutide has crossed the 30% weight loss benchmark in some patients. Where do GLP-1RAs go from here?

Anthropic launches Claude Science as big tech companies increasingly eye expansion in the wider healthcare and life sciences space.

AbbVie presented new results from the Phase III ECLIPSE trial (NCT06241313) at this year's Congress of the European Academy of Neurology (EAN).

Talawar Therapeutics will use the funds to take its AD (eczema) bispecific, TALA-125, through to Phase IIb proof-of-concept trials.

The trial of Fintepla in Dravet Syndrome and LGS was run by researchers at the Brno Epilepsy Centre in Czechia.

Seven pharma companies have been selected for the FDA PreCheck pilot – a framework intended to bolster the US drug supply chain.

Zymeworks has signed an agreement to acquire Theravance Biopharma in a cash transaction valued at approximately $929m.

Anixa Biosciences has secured patent from the Korean Ministry of Intellectual Property (MOIP) for its breast cancer vaccine technology.

Experts at HLTH Europe 2026 agreed that healthcare innovations won't meet their full potential until healthcare services can implement them.